Whitehead Institute

Nimble Therapeutics Adds Peptide Drug Development Expertise to Board of Directors

Retrieved on: 
화요일, 3월 19, 2024
Science, Radiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Infectious Diseases, Stromal cell, Amgen, American Chemical Society, University, Cornell University, Patient, Medicinal chemistry, Indiana University, Whitehead Institute, Doctor of Philosophy, Therapy, Drug development, Pharmacy, Division, Molecular biology, Takeda Oncology, Ironwood Pharmaceuticals, Pharmaceutical industry

Nimble Therapeutics announced that Dan Flynn and Brian Cali have joined the company’s Board of Directors.

Key Points: 
  • Nimble Therapeutics announced that Dan Flynn and Brian Cali have joined the company’s Board of Directors.
  • Both bring deep entrepreneurial and drug development track records that will guide Nimble as it continues to pursue its internal pipeline.
  • He currently serves on the Board of Directors of Jnana Therapeutics, a role he has held since 2018.
  • "We are pleased to welcome Daniel and Brian to our Board of Directors at this important stage of Nimble’s evolution," said Jigar Patel, founder & CEO of Nimble Therapeutics.

Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors

Retrieved on: 
화요일, 3월 12, 2024
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Pulmonary hypertension, Health care, Artificial intelligence, American Thoracic Society, Whitehead Institute, Lung transplantation, Idiopathic pulmonary fibrosis, Medical director, Biomedical Research, Pulmonology, Capital Group Companies, Gossamer, Partnership, American College, Wellesley College, American studies, Commerce, Creative, Medical education, Biomedicine, Latin American studies, International Society, Putnam Investments, MNTN, University, Senior, House, Publication, Portfolio manager, FDA, Internal medicine, Entrepreneurship, Lord Abbett, MIT, Capital, Bloomberg, GOSS, Orthostatic hypertension, IPF, Initial public offering, Partner, Idiopathic disease, PAH, Pharmaceutical industry

Skye Drynan is the Founder, CEO and Creative Director of House of Skye, Ltd., and a former Partner and Senior BioPharma Analyst at Capital Group.

Key Points: 
  • Skye Drynan is the Founder, CEO and Creative Director of House of Skye, Ltd., and a former Partner and Senior BioPharma Analyst at Capital Group.
  • Ms. Drynan joins the Board with an extensive background in finance, investment, and entrepreneurship, specializing in the biotechnology industry.
  • “The addition of Dr. Nathan to our Board signifies a pivotal moment in Gossamer’s evolution,” said Faheem Hasnain, Co-Founder, Chairman and CEO of Gossamer Bio.
  • Ms. Drynan is the Founder, CEO and Creative Director of House of Skye, Ltd., which she founded in 2016.

Calico Appoints Michael Lenardo, M.D., as Chief Scientific Officer

Retrieved on: 
목요일, 3월 28, 2024
Internal medicine, University, Natural science, Biomedicine, Alphabet, Calico (company), Immune system, SAN, Research, Science, Whitehead Institute, National academy, Biology, Biochemistry, Johns Hopkins University, NIAID, Most, Nobel, Bangladesh Technical Education Board, Birth, Biomedical Research, O.B.E, Infection, Ageing, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., March 28, 2024 /PRNewswire/ -- Calico Life Sciences LLC (Calico), a biotechnology organization focused on the biology of aging and age-related diseases, and founded by Alphabet and Arthur D. Levinson, Ph.D., today announced the appointment of Michael Lenardo, M.D., as its new Chief Scientific Officer.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 28, 2024 /PRNewswire/ -- Calico Life Sciences LLC (Calico), a biotechnology organization focused on the biology of aging and age-related diseases, and founded by Alphabet and Arthur D. Levinson, Ph.D., today announced the appointment of Michael Lenardo, M.D., as its new Chief Scientific Officer.
  • Dr. Lenardo is an accomplished molecular immunologist and geneticist whose medical research career spans four decades.
  • "Securing someone of Mike's caliber for the critical role of Chief Scientific Officer is a major achievement for Calico," said Dr. Levinson, CEO of Calico.
  • "The commitment to scientific excellence and integrity at Calico, coupled with the highly talented team, is truly impressive and reflected in the impactful progress they are making.

Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer

Retrieved on: 
화요일, 10월 10, 2023
College, Flagship Pioneering, Harbor, Therapy, Roivant Sciences, University, Novartis, Cancer, Memorial University of Newfoundland, AstraZeneca, MDNA, MIT, CMO, Harvard Medical School, Publication, College of American Pathologists, Science, Assistant, Scripps Research, Whitehead Institute, Glioblastoma, Translational medicine, Memorial University of Newfoundland Faculty of Medicine, Pharmaceutical industry, Biochemistry, Oncology, Biogen

TORONTO and HOUSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (Nasdaq: MDNA TSX: MDNA), a clinical-stage immunotherapy company focused on the development of novel Superkines, today announced the appointment of Humphrey Gardner, M.D., as Chief Medical Officer (CMO) to lead the development strategy and execution of Medicenna’s clinical programs.

Key Points: 
  • TORONTO and HOUSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (Nasdaq: MDNA TSX: MDNA), a clinical-stage immunotherapy company focused on the development of novel Superkines, today announced the appointment of Humphrey Gardner, M.D., as Chief Medical Officer (CMO) to lead the development strategy and execution of Medicenna’s clinical programs.
  • Dr. Gardner holds remarkable leadership experiences advancing immune-based therapies for cancer and other diseases from the earliest stages of development through regulatory approvals,” said Fahar Merchant, Ph.D., President and Chief Executive Officer of Medicenna.
  • Previously, he was the CMO at Stingthera, CMO in Residence at Roivant Sciences and Chief of Medical Oncology at Evelo Biosciences, a Flagship Pioneering company.
  • Dr. Gardner holds a bachelor’s degree in Biochemistry and his medical degree from the University of Cambridge.

SHORELINE BIOSCIENCES WINS A COMPREHENSIVE SUMMARY JUDGEMENT VICTORY ON ALL CLAIMS BROUGHT BY FATE THERAPEUTICS AND WHITEHEAD INSTITUTE ON IPSC GENERATION AND USE

Retrieved on: 
목요일, 9월 7, 2023
Transfer, Nobel Prize, Morrison & Foerster, Macrophage, Whitehead Institute, Ink, Cancer, Cell, Destiny, District court, Patent, Patient, SAN, IMac, ARD International Music Competition, SCNT, Mofo, Douglas v. U.S. District Court ex rel Talk America, Somatic cell nuclear transfer, Generic drug

The district court granted Shoreline's motion for summary judgement of non-infringement on all of Fate and Whitehead's patent infringement claims, ruling that the Fate/Whitehead patents did not reach Shoreline's use of iPSCs in its drug development programs as Fate and Whitehead had claimed.

Key Points: 
  • The district court granted Shoreline's motion for summary judgement of non-infringement on all of Fate and Whitehead's patent infringement claims, ruling that the Fate/Whitehead patents did not reach Shoreline's use of iPSCs in its drug development programs as Fate and Whitehead had claimed.
  • Kleanthis G. Xanthopoulos, Ph.D., Shoreline's Chairman and CEO, commented: "The district court's ruling represents a complete victory against this meritless lawsuit, which wasted significant capital and resources.
  • Fate and Whitehead tried to stretch patents about Somatic Cell Nuclear Transfer (SCNT) to cover iPSCs that Dr. Yamanaka invented and for which he won the Nobel Prize.
  • Shoreline was represented by Morrison & Foerster (MoFo) in the patent infringement litigation.

Research from the Lab of CAMP4 Co-Founder Richard Young Shows That RNA Binding to Transcription Factors Fine-Tunes Gene Expression

Retrieved on: 
수요일, 7월 5, 2023
Health, Stem Cells, Genetics, Research, Science, Pharmaceutical, Biotechnology, DNA, Whitehead Institute, DSM-IV codes, TFS, Molecular Cell, Chromatin, Transcription factor, RNA, Gene expression, Cell, Thought, Massachusetts Institute of Technology, Protein, TF, Therapy, Gene, Factorization of polynomials, Genome, Disease, Vaccine, Biology

CAMP4 Therapeutics, a biotechnology company harnessing the power of regulatory RNA to restore healthy gene expression, announced research published by the lab of co-founder Richard Young, Ph.D., in the journal Molecular Cell showing that transcription factors (TFs) interact with non-coding RNA to finely tune the regulation of gene expression.

Key Points: 
  • CAMP4 Therapeutics, a biotechnology company harnessing the power of regulatory RNA to restore healthy gene expression, announced research published by the lab of co-founder Richard Young, Ph.D., in the journal Molecular Cell showing that transcription factors (TFs) interact with non-coding RNA to finely tune the regulation of gene expression.
  • The new research published by Dr. Young’s lab reveals that many TFs also bind to RNA through a previously unrecognized domain.
  • “Until now, our knowledge of transcription factors binding to RNA was limited to a few isolated examples,” said Dr. Young.
  • “Our research shows that many transcription factors need to interact with DNA, protein, and RNA to conduct their normal gene regulation functions.

Arbor Biotechnologies Appoints Dr. Daniel Ory as Chief Medical Officer

Retrieved on: 
수요일, 4월 12, 2023
Niemann–Pick disease, MGH, Whitehead Institute, Alan, Sucampo Pharmaceuticals, Harvard College, MIT, Casma, Ara Parseghian, Washington University in St. Louis, Harvard Medical School, Internal medicine, Hospital, NPC, Therapy, Neurology, Muscular dystrophy, Global Genes, Pharmaceutical industry, Brigham, Cardiology

CAMBRIDGE, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic editing medicines, today announced the appointment of Daniel Ory, M.D., as Chief Medical Officer.

Key Points: 
  • CAMBRIDGE, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic editing medicines, today announced the appointment of Daniel Ory, M.D., as Chief Medical Officer.
  • Dr. Ory joins Arbor from Casma Therapeutics, a Third Rock Ventures start up, where he served most recently as Chief Medical Officer, responsible for overseeing its muscular dystrophy and rare oncology programs.
  • “I am pleased to welcome Dr. Ory to our executive team, who has extensive experience in the neurology, metabolic, and rare disease space, spanning both industry and academia,” said Devyn Smith, Ph.D., CEO of Arbor.
  • As a champion of rare disease research, Dr. Ory has been honored many times for his work, including the Global Genes RARE Champion of Hope Award.

Virpax Pharmaceuticals Announces Appointment of Barbara A. Ruskin, Ph.D, J.D. to the Board of Directors

Retrieved on: 
화요일, 3월 28, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Surgery, Health, Infectious Diseases, Intellectual property, Central nervous system, University, Berkeley, Harvard University, Biogen, Whitehead Institute, Innovation, Ropes & Gray, Biomedical Research, MIT, CNS, Fordham University School of Law, Fish, Molecular biology, Rope, Daubert v. Merrell Dow Pharmaceuticals, Inc., Post-traumatic stress disorder, Pain management, Vertex Pharmaceuticals, Knowledge, Hospital, Therapy, Pharmaceutical industry, IP, Biochemistry

to its Board of Directors, increasing the size of the Board to nine members.

Key Points: 
  • to its Board of Directors, increasing the size of the Board to nine members.
  • Most recently she serves as the Chief Intellectual Property and Innovation Officer for Silence Therapeutics, a Nasdaq listed international biotechnology company.
  • “With her unique background, knowledge and experience, we believe that Dr. Ruskin will be a valuable addition to our Board.
  • We are very pleased that she is joining us and look forward to her contributions,” concluded Anthony P. Mack , Chairman and CEO of Virpax.

Carcell welcomes Prof. Harvey Lodish as Chair of its Scientific Advisory Board

Retrieved on: 
월요일, 12월 19, 2022
Sanofi, Nobel Prize, European, Coronavirus Scientific Advisory Board (Turkey), Cell, Assistant, RBC, Whitehead Institute, Chemistry, Degenerative disease, National academy, National university, Student, American Association for Cancer Research, Takeda, Reticulocyte, Investment, MIT, Physiology, Stem cell, Cancer, Brown University, Genzyme, European Molecular Biology Organization, Knowledge, Multimedia, Massachusetts Institute of Technology, Biological engineering, Cell biology, American Academy, National University of Singapore, National Center for Advancing Translational Sciences, Research, Biomedical Research, Red blood cell, Takeda Oncology, Patient, Therapy, Medical device, Pharmaceutical industry, Science, Biology, Medicine, Yves Carcelle

SINGAPORE and SHANGHAI, Dec. 19, 2022 /PRNewswire/ -- Carcell Biopharma ("Carcell"), an EVX Ventures company, is pleased to announce Prof. Harvey Lodish as the Chair of the Scientific Advisory Board.

Key Points: 
  • SINGAPORE and SHANGHAI, Dec. 19, 2022 /PRNewswire/ -- Carcell Biopharma ("Carcell"), an EVX Ventures company, is pleased to announce Prof. Harvey Lodish as the Chair of the Scientific Advisory Board.
  • He joins Prof. Jianzhu Chen of the Massachusetts Institute of Technology (MIT) and Dr. Hagop Youssoufian of Brown University on Carcell's Scientific Advisory Board to propel scientific advancement of its cell and gene therapy platforms.
  • Prof. Lodish brings onboard decades of experience in biotech and especially red blood cell (RBC)-based therapeutics to the team.
  • XQ Lin, the Chairman of Carcell, commented, "We are delighted to have Prof. Lodish join us as the Chair of our Scientific Advisory Board.

Carcell welcomes Prof. Harvey Lodish as Chair of its Scientific Advisory Board

Retrieved on: 
월요일, 12월 19, 2022
Sanofi, Nobel Prize, European, Coronavirus Scientific Advisory Board (Turkey), Cell, Assistant, RBC, Whitehead Institute, Chemistry, Degenerative disease, National academy, National university, Student, American Association for Cancer Research, Takeda, Reticulocyte, Investment, MIT, Physiology, Stem cell, Cancer, Brown University, Genzyme, European Molecular Biology Organization, Knowledge, Massachusetts Institute of Technology, Biological engineering, Cell biology, American Academy, National University of Singapore, National Center for Advancing Translational Sciences, Research, Biomedical Research, Red blood cell, Takeda Oncology, Patient, Therapy, Medical device, Pharmaceutical industry, Science, Biology, Medicine, Yves Carcelle

SINGAPORE and SHANGHAI, Dec. 19, 2022 /PRNewswire/ -- Carcell Biopharma ("Carcell"), an EVX Ventures company, is pleased to announce Prof. Harvey Lodish as the Chair of the Scientific Advisory Board.

Key Points: 
  • SINGAPORE and SHANGHAI, Dec. 19, 2022 /PRNewswire/ -- Carcell Biopharma ("Carcell"), an EVX Ventures company, is pleased to announce Prof. Harvey Lodish as the Chair of the Scientific Advisory Board.
  • He joins Prof. Jianzhu Chen of the Massachusetts Institute of Technology (MIT) and Dr. Hagop Youssoufian of Brown University on Carcell's Scientific Advisory Board to propel scientific advancement of its cell and gene therapy platforms.
  • Prof. Lodish brings onboard decades of experience in biotech and especially red blood cell (RBC)-based therapeutics to the team.
  • XQ Lin, the Chairman of Carcell, commented, "We are delighted to have Prof. Lodish join us as the Chair of our Scientific Advisory Board.